PrestaShop vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Paris open-source e-commerce platform powering 300K+ shops in 175 countries at $22.1M revenue; 70M+ downloads competing with Shopify and WooCommerce with strong European SMB and French market positioning.
About
PrestaShop is a Paris-based open-source e-commerce platform powering 300,000+ online shops across 175 countries — providing SMB and mid-market merchants with free, self-hosted e-commerce software available in 75 languages plus paid modules, themes, and services through the PrestaShop Marketplace. Founded in 2007 by Bruno Lévêque and Igor Schlumberger, PrestaShop generated $22.1 million in revenue in 2024 (up from $18.3 million in 2023) through its marketplace revenue, PrestaShop Ready managed hosting, and professional services — commanding approximately 3% global e-commerce platform market share among the top 1 million sites, with 70+ million downloads and a 1 million+ merchant and developer community.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.